Genmab A/S (GMAB) stock
Close on Nov 18, 2026
Earnings
Genmab A/S's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Genmab A/S's earnings releases, newest first
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Genmab A/S's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Revenue | FY2023 | 15,500 – 16,500 | – | New | Aug 3, 2023 |
| Operating profit | FY2023 | 4500 – 6000 | – | New | Aug 3, 2023 |
| Operating expenses | FY2023 | 10,400 – 10,900 | – | New | Aug 3, 2023 |
| revenue | FY2024 | 20.5 – 21.7 | – | New | Aug 8, 2024 |
| operating profitGAAP | FY2024 | 4.9 – 6.7 | – | New | Aug 8, 2024 |
| operating profit excluding acquisition and integration related chargesnon-GAAP | FY2024 | 5.3 – 7.1 | – | New | Aug 8, 2024 |
| operating expensesGAAP | FY2024 | 14.1 – 14.7 | – | New | Aug 8, 2024 |
| operating expenses (excluding acquisition and integration related charges)non-GAAP | FY2024 | 13.7 – 14.3 | – | New | Aug 8, 2024 |
Guidance history
Every forecast Genmab A/S put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 8, 2024 | operating profit | FY2024 | 4.9 – 6.7 | New |
| Aug 8, 2024 | operating profit excluding acquisition and integration related charges | FY2024 | 5.3 – 7.1 | New |
| Aug 8, 2024 | operating expenses | FY2024 | 14.1 – 14.7 | New |
| Aug 8, 2024 | operating expenses (excluding acquisition and integration related charges) | FY2024 | 13.7 – 14.3 | New |
| Aug 8, 2024 | revenue | FY2024 | 20.5 – 21.7 | New |
| Aug 3, 2023 | Operating profit | FY2023 | 4500 – 6000 | New |
| Aug 3, 2023 | Operating expenses | FY2023 | 10,400 – 10,900 | New |
| Aug 3, 2023 | Revenue | FY2023 | 15,500 – 16,500 | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Genmab A/S filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
See a number that looks wrong?